LIMN Liminatus Pharma, Inc.

Nasdaq liminatuspharma.com


$ 1.32 $ -0.13 (-8.9 %)    

Tuesday, 14-Oct-2025 14:58:30 EDT
QQQ $ 601.98 $ 6.76 (1.14 %)
DIA $ 464.69 $ 7.68 (1.68 %)
SPY $ 665.30 $ 8.01 (1.22 %)
TLT $ 90.83 $ 0.19 (0.21 %)
GLD $ 381.57 $ 3.27 (0.86 %)
$ 1.41
$ 1.45
$ 1.32 x 201
$ 1.36 x 100
$ 1.25 - $ 1.46
$ 1.12 - $ 33.66
241,472
na
32.85M
$ -1.11
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 10-04-2025 06-30-2025 10-Q
2 05-31-2025 03-31-2025 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

Core News & Articles

Liminatus Pharma, Inc. (NASDAQ:LIMN), a preclinical-stage biopharmaceutical company dedicated to the development of targeted ca...

Core News & Articles

Liminatus Pharma, Inc. (NASDAQ:LIMN), a preclinical-stage biopharmaceutical company dedicated to the development of targeted ca...

Core News & Articles

Liminatus Pharma, Inc. (NASDAQ:LIMN), a preclinical-stage biopharmaceutical company dedicated to the development of targeted ca...

Core News & Articles

Liminatus Pharma, Inc. has entered into a Memorandum of Understanding (MOU) to form a research and development consortium with ...

 us-stocks-likely-to-open-higher-sp-500-sees-average-gain-of-61-in-2nd-half-expert-says

U.S. futures rose on Wednesday after a mixed close on Tuesday. Futures of major benchmark indices were trading slightly higher.

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION